CN107029275A - 湿式敷料 - Google Patents
湿式敷料 Download PDFInfo
- Publication number
- CN107029275A CN107029275A CN201610076608.1A CN201610076608A CN107029275A CN 107029275 A CN107029275 A CN 107029275A CN 201610076608 A CN201610076608 A CN 201610076608A CN 107029275 A CN107029275 A CN 107029275A
- Authority
- CN
- China
- Prior art keywords
- analgesic
- wet dressing
- film
- dressing
- wet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000202 analgesic effect Effects 0.000 claims abstract description 44
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 43
- 239000010408 film Substances 0.000 claims description 39
- 239000000835 fiber Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 15
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical group COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims description 12
- 239000000017 hydrogel Substances 0.000 claims description 12
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 claims description 8
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 7
- 229940041616 menthol Drugs 0.000 claims description 7
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 235000017663 capsaicin Nutrition 0.000 claims description 6
- 229960002504 capsaicin Drugs 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 6
- 241000402754 Erythranthe moschata Species 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000000416 hydrocolloid Substances 0.000 claims description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- 235000003717 Boswellia sacra Nutrition 0.000 claims description 4
- 240000007551 Boswellia serrata Species 0.000 claims description 4
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 239000004863 Frankincense Substances 0.000 claims description 4
- 229950004580 benzyl nicotinate Drugs 0.000 claims description 4
- 229930008380 camphor Natural products 0.000 claims description 4
- 229960000846 camphor Drugs 0.000 claims description 4
- 239000010634 clove oil Substances 0.000 claims description 4
- 229960001193 diclofenac sodium Drugs 0.000 claims description 4
- 239000006261 foam material Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 claims description 4
- 229920000247 superabsorbent polymer Polymers 0.000 claims description 4
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 3
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 3
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims description 3
- 244000163122 Curcuma domestica Species 0.000 claims description 3
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 3
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 3
- 229920001131 Pulp (paper) Polymers 0.000 claims description 3
- 241000304195 Salvia miltiorrhiza Species 0.000 claims description 3
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims description 3
- 239000005844 Thymol Substances 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 239000011425 bamboo Substances 0.000 claims description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 3
- 229940116229 borneol Drugs 0.000 claims description 3
- 239000003610 charcoal Substances 0.000 claims description 3
- 235000017803 cinnamon Nutrition 0.000 claims description 3
- 235000003373 curcuma longa Nutrition 0.000 claims description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 3
- 210000003746 feather Anatomy 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 239000004745 nonwoven fabric Substances 0.000 claims description 3
- 229960000790 thymol Drugs 0.000 claims description 3
- 235000013976 turmeric Nutrition 0.000 claims description 3
- HCJMNOSIAGSZBM-UHFFFAOYSA-N 6-methylsalicylic acid Chemical group CC1=CC=CC(O)=C1C(O)=O HCJMNOSIAGSZBM-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 244000061520 Angelica archangelica Species 0.000 claims description 2
- 244000004281 Eucalyptus maculata Species 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims 1
- 240000004670 Glycyrrhiza echinata Species 0.000 claims 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims 1
- 240000003553 Leptospermum scoparium Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 239000000020 Nitrocellulose Substances 0.000 claims 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- -1 indomethasacin Chemical compound 0.000 claims 1
- 229940010454 licorice Drugs 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 abstract description 45
- 208000002193 Pain Diseases 0.000 abstract description 16
- 230000036407 pain Effects 0.000 abstract description 16
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 239000011148 porous material Substances 0.000 abstract description 4
- 238000011084 recovery Methods 0.000 abstract description 4
- 239000004615 ingredient Substances 0.000 abstract description 3
- 206010051373 Wound haemorrhage Diseases 0.000 abstract description 2
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 235000015097 nutrients Nutrition 0.000 abstract description 2
- 230000008961 swelling Effects 0.000 abstract description 2
- 230000037314 wound repair Effects 0.000 abstract description 2
- 230000036651 mood Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 43
- 230000029663 wound healing Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 210000000416 exudates and transudate Anatomy 0.000 description 7
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 239000003999 initiator Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical group COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 238000000016 photochemical curing Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 230000001815 facial effect Effects 0.000 description 3
- 210000001126 granulation tissue Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- VEDLJOPBQDOZLD-UHFFFAOYSA-N ethane-1,2-diol;2-hydroxybenzoic acid Chemical compound OCCO.OC(=O)C1=CC=CC=C1O VEDLJOPBQDOZLD-UHFFFAOYSA-N 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229960002389 glycol salicylate Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 235000015816 nutrient absorption Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000031074 Reinjury Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003847 radiation curing Methods 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000004583 superabsorbent polymers (SAPs) Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种湿式敷料，其添加温感镇痛消炎因子于敷料中，用以减缓患者伤口处的不舒适感，或促进肌肤保养成分的吸收。利用本发明的湿式敷料中的冷感镇痛消炎因子可镇痛消肿、减缓伤口出血或渗液，缓和患者不舒适的情绪；而利用本发明的湿式敷料中的热感镇痛消炎因子可促进血液微循环加速伤口修复，或扩张毛孔加速营养成分吸收，加速恢复肌肤的活力。
Description
技术领域
本发明系关于一种湿式敷料，特别系包含一种或一种以上的温感镇痛消炎因子分散于其中的湿式敷料。
背景技术
皮肤是人体最大的组织器官，亦是抵抗外来病源的第一道防线，若发生创伤时，迅速愈合恢复防御力实属刻不容缓的要务。
敷料是一类重要的医疗与化妆用品，其中医用敷料是覆盖伤口的材料，主要功能是控制伤口渗液、保护伤口免受细菌及尘粒的污染。传统纱布敷料虽能保护伤口，但对伤口愈合无促进作用，渗液管理能力差，更换敷料时容易因沾粘伤口新生组织导致反复损伤与疼痛、瘢痕形成等不适反应，故难以满足现代人对外观及时效的诉求。
1958年Odland发现保持完整水泡的伤口，比水泡破裂的伤口愈合的速度要快。1962年伦敦大学Winter博士以猪试验，在伤口上覆盖聚氨酯，证实湿式环境的伤口愈合速度比干式愈合快一倍。1963年Hinman及Maibach人体实验证实，人身上的伤口湿润也比干燥伤口愈合要快。1970年Rovee人体实验，亦证实湿润伤口的上皮细胞移行增生的速度较快，能加速伤口的愈合，于是湿润伤口愈合(MWH,moist wound healing)观念开始建立。
新型湿式敷料大体可归类为水胶体(Hydrocolloids)、水凝胶(Hydrogels)、藻酸盐(Alginates Hydrofibers)、泡沫(海绵)(Foam)以及含银抗菌敷料等类，其特性为1.有效吸收伤口渗液保持适当湿润，促进伤口愈合；2.不粘连新生的肉芽组织，更换无痛；3.防止痂皮形成，减少瘢痕形成等。
然而，泡沫(海绵)与藻酸盐类敷料虽可大量吸收渗液或止血，但无法有效隔绝细菌并保护伤口；水胶体、水凝胶或含银类敷料虽可保护伤口，创造湿润环境，但过薄的敷料吸收渗液能力有限，过厚的敷料又影响伤口透气性与方便性。
急性创伤或整容手术后，医师大多建议患者2天内冷敷，此时需阻止血液及组织液的渗出，冷敷可使新创伤口的皮下毛细血管收缩，减少出血渗液，减轻疼痛，具有降温、止血、止痛、防止继发感染和血肿增大等作用。
而创伤2天后，伤口已由出血渗液期转入修复期，此时换成热敷可使局部毛细血管松弛扩张，血流加快，提高新陈代谢水准，促进创伤组织活血、化瘀、生肌、消炎、消肿、止痛及癍痕组织软化等作用，进而促进愈合。
但冷敷或热敷一般使用非固定式的毛巾、冷热水袋或冷热敷垫，然而，除了需避免其接触伤口造成感染，还需随时注意温度不可过低或过烫，此外，还需以手托扶增加患者负担，并影响治疗效果。
为解决上述问题，亟需开发既能主动降低伤口的出血渗液且在伤口愈合期又能促进患部血液循环、维持伤口湿润、加速伤口肉芽组织愈合的新敷料。
发明内容
本发明的要目的在于提供一种湿式敷料，其能主动降低伤口的出血渗液，在伤口愈合期又能促进患部血液循环，维持伤口湿润，加速伤口肉芽组织愈合。
为实现上述目的，本发明公开了一种湿式敷料，其包含一或一种以上的温感镇痛消炎因子分散于该湿式敷料中。
于一较佳实施例中，该湿式敷料系为伤口敷料或肌肤敷料膜。
于另一较佳实施例中，该伤口敷料系选自由水胶体(Hydrocolloids)、藻酸盐(Alginates Hydrofibers)、水凝胶(Hydrogels)、泡沫(海绵)(Foam)及硝酸纤维素(Pyroxyline)构成的群组中的至少一种所组成。
于另一较佳实施例中，该肌肤敷料膜系选自由生物纤维膜、不织布膜、羽丝绒膜、竹炭膜、木浆膜、蚕丝膜、纸纤膜、纤维、纤维海棉、泡沫材料、超级吸收聚合物、水凝胶材料及凝胶材料构成的群组中的至少一种所组成。
于另一较佳实施例中，该温感镇痛消炎因子系进一步区分为冷感镇痛消炎因子及热感镇痛消炎因子。
于另一较佳实施例中，该冷感镇痛因子系选自由甲基水杨酸(MethylSalicylate)、乙二醇水杨酸(Glycol Salicylate)、双氯芬酸钠(DiclofenacSodium)、引朵美洒辛(Indomethacin)、薄荷脑(Menthol)、樟脑(Camphor)、百里香酚(Thymol)、甘草(Glycyrretinic acid)、丹参(Salvia miltiorrhiza)、尿囊素(Allantoin)、茶树精油(Tea Tree Oil)、丁香油(Clove oil)及冰片(Borneol)所组成的群组。
于另一较佳实施例中，该热感镇痛消炎因子系选自由辣椒素(Capsaicin)、烟酸苄酯(Nicotinic acid benzyl ester)、尤加利(Eucalyptus oil)、姜黄(Curcumin)、麝香(musk)、肉桂(Cinnamon)、当归(Angelica)及乳香(Frankincense)所组成的群组。
于另一较佳实施例中，该温感镇痛消炎因子系占湿式敷料总重量的0.01～10wt％。
于另一较佳实施例中，该湿式敷料的厚度约为0.1～5毫米。
依据上述本发明的湿式敷料，其系以冷、热冷、热敷的生理疗效，结合原湿式敷料方便贴附、维持伤口湿润、保护伤口免受感染等优点，加速缩短伤口愈合时间与减轻疼痛不适感。而本发明的湿式敷料结合温感镇痛消炎因子，应用于伤口，能使伤口降温止痛、局部血管收缩达到止血、消肿、消炎等作用，大大减轻患者不舒服感及渗液量；在伤口24～48小时的后使用，能使伤口局部血管扩张加速血液循环，纠正组织缺氧，增强白细胞吞噬功能，改善局部组织代谢和营养状况，加速受损组织康复等积极效果。另外，本发明的湿式敷料其低敏、透气、服贴方便的特性，结合温感镇痛消炎因子中的冷感镇痛消炎因子，每天可长可短直接贴附于扭伤、瘀伤、轻微灼伤、发热、头痛、牙痛、流鼻血、昆虫咬伤、青春痘等患处而不引起肌肤过敏。而温感镇痛消炎因子中的热感镇痛消炎因子，每天可长可短直接贴附于风湿、关节炎、背痛、肌肉酸痛、颈部酸痛、生理期疼痛及运动伤害等患处而不引起肌肤过敏。
再者，本发明的湿式敷料应用至面膜，利用热敷特性迫使肌肤毛孔张开、加速血液循环，促进面膜上有效成分的清洁代谢或营养吸收深入肌肤深层，渗透效果更胜于一般面膜的使用。
附图说明
图1：为本发明敷料结构层的放大图。
图2：本发明应用的医用敷料的侧面结构示意图。
图3：绘示本发明应用的敷膜的侧面结构示意图。
具体实施方式
本文中术语「一」或「一种」当与「包含」连用于申请专利范围或说明书中，可能代表有一个，但也符合「一或多个」或「至少一个」。
本发明的湿式敷料
本发明的一主要目的在于提供一种湿式敷料，其包含一或一种以上的温感镇痛消炎因子分散于该湿式敷料中。
于一较佳实施例中，该湿式敷料系为伤口敷料或肌肤敷料膜。
于另一较佳实施例中，该伤口敷料系选自由水胶体(Hydrocolloids)、藻酸盐(Alginates Hydrofibers)、水凝胶(Hydrogels)、泡沫(海绵)(Foam)及硝酸纤维素(Pyroxyline)构成的群组中的至少一种所组成。
于另一较佳实施例中，该肌肤敷料膜系选自由生物纤维膜、不织布膜、羽丝绒膜、竹炭膜、木浆膜、蚕丝膜、纸纤膜、纤维、纤维海棉、泡沫材料、超级吸收聚合物、水凝胶材料及凝胶材料构成的群组中的至少一种所组成。
于另一较佳实施例中，该温感镇痛消炎因子系进一步区分为冷感镇痛消炎因子及热感镇痛消炎因子，添加复数个该温感镇痛消炎因子时，其功效具有可加成性。
于另一较佳实施例中，该冷感镇痛消炎因子系选自由甲基水杨酸及其衍生物、双氯芬酸钠(Diclofenac Sodium)、引朵美洒辛(Indomethacin)、薄荷脑(Menthol)、樟脑(Camphor)、百里香酚(Thymol)、甘草(Glycyrretinic acid)、丹参(Salvia miltiorrhiza)、尿囊素(Allantoin)、茶树精油(Tea Tree Oil)、丁香油(Clove oil)及冰片(Borneol)所组成的群组中的至少一种组成。
于另一较佳实施例中，该水杨酸的衍生物为甲基水杨酸(MethylSalicylate)、乙二醇水杨酸(Glycol Salicylate)。
于另一较佳实施例中，该热感因子系选自由辣椒素(Capsaicin)、烟酸苄酯(Nicotinic acid benzyl ester)、尤加利(Eucalyptus oil)、姜黄(Curcumin)、麝香(musk)、肉桂(Cinnamon)、当归(Angelica)及乳香(Frankincense)所组成的群组中的至少一种组成。
上述该温感镇痛消炎因子较佳系占湿式敷料总重量的0.01～10wt％。且较佳系经机械搅拌方式，使其均匀分散于未固化的湿式敷料的材料中，以促进微小化的温感镇痛消炎因子的有效分散性与包覆缓释性。
上述该未固化的湿式敷料材料，较佳系包含不参与人体新陈代谢、具优良生物惰性、生物相容性、药物缓释载体的粘连剂和成膜剂的聚乙烯吡咯烷酮(PVP)与聚乙二醇(PEG)结合光引发剂(photo-initiator)，在紫外光或可见光(ex.波长450nm)照射下，液态低聚物(ex.单体)经光固化的交联聚合而形成不溶涂膜的过程。2004年5月北美辐射固化国际会议上，归纳光固化技术所具有的五个特点(5E)，包含：高效(Efficient)、适应性广(Enabling)、经济(Economical)、节能(Energy-saving)和环境友好(Environmental Friendly)。由于光固化技术具有上述较佳的特征，因此，自1968年德国Bayer开发光固化的木器涂料以来，已广泛应用于涂料、油墨、胶粘剂、微电子和生物材料等领域。
于另一较佳实施例中，该湿式敷料的厚度，较佳但不限于，约为0.1～5毫米，且上述该湿式敷料的材料较佳可为一种或一种以上选自由纤维、纤维海绵、泡沫材料、超级吸收聚合物、水凝胶材料、凝胶材料所组成的群组。
以下实施例不应视为过度地限制本发明。本发明所属技术领域中具有通常知识者可在不背离本发明的精神或范畴的情况下对本文所讨论的实施利进行修改及变化，而仍属于本发明的范畴。
实例1
请参阅图1一并进行说明，图1系本发明的温感镇痛消炎敷料100的成分结构示意图，包含湿式敷料110、及温感镇痛消炎因子120。温感镇痛消炎因子120的实施例A系以乙二醇水杨酸0.25wt％、薄荷醇1wt％、樟脑2wt％、尤加利精油1wt％组成；实施例B系以乙二醇水杨酸0.2wt％、薄荷醇0.2wt％、辣椒素0.2wt％组成，添加于液态未固化的水凝胶湿式敷料110的材料中，经机械搅拌方式使温感镇痛消炎因子120均匀分散。未固化的湿式敷料110的水凝胶材料，包含聚乙烯吡咯烷酮(PVP)2wt％、聚乙二醇(PEG)15％高分子与液态低聚物，结合光引发剂(photo-initiator)，在紫外光照射下，液态低聚物经光固化的交联聚合形成不溶涂膜的温感镇痛消炎敷料100，厚度约0.3毫米(mm)。由于该水凝胶材料与制程并非本发明的重点，因此不多赘述。
请参阅图2，图2系以具单面粘合剂的薄膜210粘合于温感镇痛消炎敷料100的上，且薄膜210的表面积大于敷料100的表面积，用以提供对敷料100与肌肤的粘合(单面粘合剂未绘示)，肌肤粘合区域为一供氧和湿气交换的密封环境，隔绝微生物与污染物进入伤口，以促进伤口处于潮湿而不过度浸润或干燥现象。
在上述的实施例中，以10名大小深浅相似的急性擦伤患者(无慢性病)，年龄介于15～40岁，受创12小时内，先以生理食盐水将伤口清洗干净(换药时亦然)，5名患者以薄膜210含温感镇痛消炎敷料100为实施例A，5名患者以薄膜210含湿式敷料110(不含有温感镇痛消炎因子120)为比较例，分别贴附伤口患部，每日换敷料，实施例A组患者第3天更换实施例B的敷料100。
患者疼痛程度以NPIS(Numeric Pain Intensity Scale)分级法表示：0-10代表不同程度的疼痛，0无痛、1-3轻度疼痛、4-6中度疼痛、7-10重度疼痛。患者根据自己的感觉圈出一个数字，10名患者疼痛感觉平均值如下列表一所示：
表1
伤口愈合疗效分级如下：无效：伤口无改善；好转：伤口缩小30～70％；显效：伤口缩小70％以上；痊愈：伤口愈合。
10名患者不同时间的疗效如下列表2所示：
表2
于上述实施例中，含薄膜210的温感镇痛消炎敷料100不仅方便直接贴附患部，并可针对不同的敷料用品(例如伤口、轻度灼伤、昆虫咬伤、发烧、头痛、牙痛、流鼻血、生理疼痛等)所需的功效，选择添加适当的温感镇痛消炎因子120，以减轻患部不舒适感及加速复原。
实例2
请参阅图3，敷膜300包含本发明实施例C的温感镇痛消炎因子120及亲水纤维310的示意图。该敷膜300是将亲水纤维310中的高分子材料(例如聚烯烃纤维)与高分子亲水改质剂掺混时，同步添加温感镇痛消炎因子120系以薄荷醇0.2wt％、辣椒素0.2wt％组成，以熔喷(Meltblown)或纺粘(Spunbond)的方式制得。由于该制程并非本发明的重点，因此不多赘述。
具有亲水性与吸水性的亲水纤维310可针对面膜保养品(例如保湿面膜、美白面膜、舒缓眼膜等)所需的功效添加不同的成分。本发明于上述该实施方式中，该敷膜300不仅具有亲水纤维310的保养功效，还具有热敷特性的温感镇痛消炎因子120，使敷膜300接触肌肤时迫使毛孔张开、加速血液循环，促进亲水纤维310上有效成分的清洁代谢或营养吸收并深入肌肤深层，渗透效果更胜于一般亲水纤维310膜的使用。
本发明添加温感镇痛消炎因子于敷料中，用以减缓患者伤口处的不舒适感，或促进肌肤保养成分的吸收。利用本发明的冷感敷料可镇痛消肿、减缓伤口出血或渗液，缓和患者不舒适的情绪；热感敷料可促进血液微循环加速伤口修复，或扩张毛孔加速营养成分吸收，加速恢复肌肤的活力。
Claims (10)
1.一种湿式敷料，其特征在于：包含一或一种以上的温感镇痛消炎因子分散于该湿式敷料中。
2.如权利要求1的湿式敷料，其特征在于，该湿式敷料为伤口敷料或肌肤敷料膜。
3.如权利要求2的湿式敷料，其特征在于，该伤口敷料选自由水胶体、藻酸盐、水凝胶、泡沫及硝酸纤维素构成的群组中的至少一种所组成。
4.如权利要求2的湿式敷料，其特征在于，该肌肤敷料膜选自由生物纤维膜、不织布膜、羽丝绒膜、竹炭膜、木浆膜、蚕丝膜、纸纤膜、纤维、纤维海棉、泡沫材料、超级吸收聚合物、水凝胶材料及凝胶材料构成的群组中的至少一种所组成。
5.如权利要求1至4任一项的湿式敷料，其特征在于，该温感镇痛消炎因子进一步区分为冷感镇痛消炎因子及热感镇痛消炎因子。
6.如权利要求5的湿式敷料，其特征在于，该冷感镇痛消炎因子选自由水杨酸及其衍生物、双氯芬酸钠、引朵美洒辛、薄荷脑、樟脑、百里香酚、甘草、丹参、尿囊素、茶树精油、丁香油及冰片所组成的群组中的至少一种组成。
7.如权利要求6的湿式敷料，其特征在于，该水杨酸的衍生物为甲基水杨酸和/或乙二醇水杨酸。
8.如权利要求5的湿式敷料，其特征在于，该热感镇痛消炎因子系选自由辣椒素、烟酸苄酯、尤加利、姜黄、麝香、肉桂、当归及乳香所组成的群组中的至少一种组成。
9.如权利要求5的湿式敷料，其特征在于，该温感镇痛消炎因子占湿式敷料总重量的0.01～10wt％。
10.如权利要求5的湿式敷料，其特征在于，该湿式敷料的厚度为0.1～5毫米。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610076608.1A CN107029275A (zh) | 2016-02-04 | 2016-02-04 | 湿式敷料 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610076608.1A CN107029275A (zh) | 2016-02-04 | 2016-02-04 | 湿式敷料 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107029275A true CN107029275A (zh) | 2017-08-11 |
Family
ID=59532867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610076608.1A Pending CN107029275A (zh) | 2016-02-04 | 2016-02-04 | 湿式敷料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107029275A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022226857A1 (zh) * | 2021-04-29 | 2022-11-03 | 美丽康生技股份有限公司 | 一种用于刺青护色的湿式敷料及其使用方法 |
| CN116785490A (zh) * | 2023-05-18 | 2023-09-22 | 吉林瑞果科技有限公司 | 一种缓解延迟性肌肉酸痛的功能性敷料及其制备方法 |
| WO2025177038A1 (en) * | 2024-02-21 | 2025-08-28 | Nanodocks Technology Limited | A method for preparing a dry facial mask and a dry facial mask prepared by the method |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014885A (zh) * | 2008-04-21 | 2011-04-13 | 麦克内尔-Ppc股份有限公司 | 双喷雾罐式局部用药递送装置 |
| CN102227198A (zh) * | 2008-12-10 | 2011-10-26 | 花王株式会社 | 发热器具 |
| CN102245144A (zh) * | 2008-12-15 | 2011-11-16 | 金伯利-克拉克环球有限公司 | 身体感觉型吸收性物品 |
| CN103313732A (zh) * | 2010-11-12 | 2013-09-18 | 日产化学工业株式会社 | 含有脂质肽型胶凝剂和高分子化合物的凝胶片 |
-
2016
- 2016-02-04 CN CN201610076608.1A patent/CN107029275A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014885A (zh) * | 2008-04-21 | 2011-04-13 | 麦克内尔-Ppc股份有限公司 | 双喷雾罐式局部用药递送装置 |
| CN102227198A (zh) * | 2008-12-10 | 2011-10-26 | 花王株式会社 | 发热器具 |
| CN102245144A (zh) * | 2008-12-15 | 2011-11-16 | 金伯利-克拉克环球有限公司 | 身体感觉型吸收性物品 |
| CN103313732A (zh) * | 2010-11-12 | 2013-09-18 | 日产化学工业株式会社 | 含有脂质肽型胶凝剂和高分子化合物的凝胶片 |
Non-Patent Citations (6)
| Title |
|---|
| 唐建华: "《家庭用药指南》", 31 January 2005 * |
| 方方等: "《协和皮肤外科学》", 31 May 2007, 中国协和医科大学出版社 * |
| 温辉梁: "《生物化工产品生产技术》", 31 December 2004 * |
| 石兰萍: "《临床外科护理基础与实践》", 31 January 2013 * |
| 胡玉兰: "《医院外用制剂研究》", 30 November 2004 * |
| 轻工业标准化编辑出版委员会: "《中国轻工业标准汇编化妆品卷（第二版）》", 31 May 2012 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022226857A1 (zh) * | 2021-04-29 | 2022-11-03 | 美丽康生技股份有限公司 | 一种用于刺青护色的湿式敷料及其使用方法 |
| CN116785490A (zh) * | 2023-05-18 | 2023-09-22 | 吉林瑞果科技有限公司 | 一种缓解延迟性肌肉酸痛的功能性敷料及其制备方法 |
| WO2025177038A1 (en) * | 2024-02-21 | 2025-08-28 | Nanodocks Technology Limited | A method for preparing a dry facial mask and a dry facial mask prepared by the method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kus et al. | Wound dressings–a practical review | |
| Rezvani Ghomi et al. | Wound dressings: Current advances and future directions | |
| CN104383585B (zh) | 一种三维纳米复合材料创可贴及其制备和使用方法 | |
| CN204931986U (zh) | 一种高吸湿性防粘医用敷料 | |
| CN201676083U (zh) | 一种治疗烧烫伤、创伤的活性银离子抗菌敷料 | |
| CN112545756A (zh) | 一种医用臭氧油-硅酮泡沫敷贴的制备方法 | |
| CN204655268U (zh) | 一种藻酸盐医用敷料 | |
| CN107029275A (zh) | 湿式敷料 | |
| Mohiuddin | A thoroughgoing detail of surgical dressings | |
| TWI600439B (zh) | 皮膚敷料添加物及其應用 | |
| CN105461856A (zh) | 一种用于光子治疗的水凝胶及其制备方法 | |
| Shete et al. | A comprehensive review on wound dressings and their comparative effectiveness on healing of contaminated wounds and ulcers | |
| CN104324412B (zh) | 一种竹原壳聚糖功能性敷料 | |
| TW202102273A (zh) | 防水透氣濕式敷料 | |
| CN107519151A (zh) | 一种液体创口贴及其制备方法 | |
| CN218792766U (zh) | 一种壳聚糖杀菌敷料贴 | |
| CN110101899A (zh) | 一种医用水胶体敷料及其制备方法 | |
| CN111956859B (zh) | 一种含中药成分的抗菌止血创可贴及其制备方法 | |
| CN206044823U (zh) | 一种医用纱布 | |
| CN204840393U (zh) | 一种可视性护创敷料 | |
| CN210114573U (zh) | 一种新型抗菌镇痛医用敷料 | |
| CN110916900A (zh) | 一种水凝胶医用敷料及其制备方法 | |
| CN211156691U (zh) | 基于促进创面愈合的湿润环境维持技术的医用贴 | |
| CN212037940U (zh) | 带染色卡的透明可视无菌敷料贴 | |
| CN115400254A (zh) | 一种如意金黄散创可贴及研究流程 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170811 |
|
| WD01 | Invention patent application deemed withdrawn after publication |